Showing 1 - 10 of 14
Persistent link: https://www.econbiz.de/10003680575
"It is well known that public or pooled insurance coverage can induce a form of ex-ante moral hazard: people make inefficiently low investments in self-protective activities. This paper points out another ex-ante moral hazard that arises through an induced innovation externality. This...
Persistent link: https://www.econbiz.de/10003681157
Persistent link: https://www.econbiz.de/10009156139
Persistent link: https://www.econbiz.de/10009671878
Persistent link: https://www.econbiz.de/10011411303
Intelligently allocating research effort and funds requires deciding whether to build on recent advances or on more established knowledge. When recent advances create superior opportunities for invention, their adoption as research inputs in the invention process promotes technological progress....
Persistent link: https://www.econbiz.de/10013065176
It is well known that public or pooled insurance coverage can induce a form of ex-ante moral hazard: people make inefficiently low investments in self-protective activities. This paper points out another ex-ante moral hazard that arises through an induced innovation externality. This alternative...
Persistent link: https://www.econbiz.de/10012772375
This paper examines whether the composition of medical research responds to changes in disease incidence and research opportunities. The paper also provides new evidence on induced pharmaceutical innovation. In both cases we use the change in the demographic structure of the market (measured by...
Persistent link: https://www.econbiz.de/10012750249
As an empirical example of this externality, we analyze the innovation induced by the obesity epidemic. Obesity is associated with an increase in the incidence of many diseases. The induced innovation hypothesis is that an increase in the incidence of a disease will increase technological...
Persistent link: https://www.econbiz.de/10012464784
This paper examines whether the composition of medical research responds to changes in disease incidence and research opportunities. The paper also provides new evidence on induced pharmaceutical innovation. In both cases we use the change in the demographic structure of the market (measured by...
Persistent link: https://www.econbiz.de/10012464785